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Alterations in the arterial partial pressure of oxygen (O2) and
carbon dioxide (CO2) lead to changes in cerebral blood ﬂow and
vasculature (Kety and Schmidt, 1948a), and this response, when used
in combination with a variety of imaging techniques, has been used
to study brain physiology and disease for many years (Aaslid et al.,
1989; Battisti-Charbonney et al., 2011; Novack et al., 1953). Magnetic
resonance imaging (MRI) is a safe, non-invasive, repeatable technique
with high spatial resolution, which can provide detailed structural
and functional information about the brain. In this paper, we deﬁne
respiratory challenge MRI as the modiﬁcation of arterial oxygen
(PaO2) and/or carbon dioxide (PaCO2) concentration to induce a
change in cerebral function or metabolism which is then measured by
MRI. This approach has been used for some time for optimization and
calibration of fMRI sequences (Hoge, 2012), but there is increasing
interest in the use of functional and/or perfusion MRI to examine
brain pathophysiology. In particular, cerebral blood ﬂow, oxygenation,
metabolic rate and microvascular function in diseases such as stroke
(Dani et al., 2010), dementia (Cantin et al., 2011), epilepsy
(Kalamangalam et al., 2012) and brain neoplasm (Hsu et al., 2010;
Yetkin and Mendelsohn, 2002).
A number of approaches have been explored. These can range from
simplemodiﬁcation of respiratory rate, includingbreath hold (Hsu et al.,
2010) and hyperventilation, to complex modelling of both respiratory
parameters and brain signal change (Mutch et al., 2012; Shen et al.,
2011). Whilst excellent articles reviewing the rationale and uses of
these procedures are available (see Krainik for a recent review of func-
tional imaging of brain perfusion (Krainik et al., 2013)), there are signif-
icant practical challenges in undertaking these methods. The aim of this
review is to [1] review the rationale for respiratory challenge MRI in
brain disease, [2] discuss techniques, equipment, monitoring and plan-
ning such experiments, and [3] propose some recommendations for op-
timization of these studies.Table 1
Deﬁnitions and relevant normal values.
Parameter Abbreviation Deﬁnition
Cerebral blood ﬂow CBF The volume of blood passing thro
time i.e. rate. This is usually deﬁn
minute.
Cerebral blood volume CBV The fraction of a tissue volume oc
Cerebral metabolic rate for oxygen CMRO2 The amount of oxygen consumed
Cerebrovascular reactivity CVR Cerebral blood ﬂow, or BOLD sign
measured as a percentage change
Arterial gas concentration PaO2 PaCO2 Partial pressure of oxygen or carb
molecules dissolved in plasma.
End-tidal gas tension EtO2 EtCO2 The partial pressure or maximum
dioxide at the end of an exhaled b
Fraction of inspired gas FiO2 FiCO2 The fraction or percentage of oxy
breathed by the subject. Normal a
Oxygen saturation SaO2 The percentage of haemoglobin m
blood.
SvO2
Oxygen content CaO2 The amount of oxygen in the bloo
Cerebrovascular resistance The resistance to the passage of b
Autoregulation Cerebral vascular bed alters vascu
the face of changes in systemic bl
Vascular steal A stimulus results in the redistrib
exhausted cerebrovascular reactiv
with preserved vasodilatory capa2. Rationale
The human brain employs an elegant system of regulation of cere-
bral blood ﬂow (CBF) to ensure adequate delivery of O2 and nutrients
to brain tissue, according to need and regardless of changes in blood
pressure, oxygenation or other factors. CBF is determined by the follow-
ing equation:
CBF ¼ Cerebralperfusionpressure CPPð Þ
Cerebrovascularresistance
:
Normal global CBF is around 50 mL/100 g/min (Kety and Schmidt,
1948b) with higher values in grey compared to white matter
(Leenders et al., 1990) (see Table 1 for further deﬁnitions). However,
CBF varies according to age, time of day, anatomical area and neuronal
activity in order to maintain adequate nutrient delivery. The principle
mechanism by which CBF is adjusted according to demand is by chang-
ing cerebrovascular resistance. This is governed by small cerebral ves-
sels, particularly pre-capillary arterioles (b100 μm) (Wei et al., 1980),
which are able to change calibre in response to a number of stimuli, a
process known as cerebrovascular reactivity (CVR). Capillaries may
also have an important role in vasoreactivity through the action of
pericytes (Hall et al., 2014). If CVR is impaired, then increased CBF will
not occur when required by brain activity.
Whilst a variety of methods exist for measuring CBF, there are dif-
ﬁculties in obtaining accurate, quantiﬁable CBF measurements, in-
cluding interindividual variability (Leenders et al., 1990), external
factors (Laurent et al., 2006), and inaccuracies in modelling methods
(Eskey and Sanelli, 2005). Large patient groups or large disease-
related effects may be needed to detect differences in baseline CBF
in disease states.Normal values
ugh the brain parenchyma in a deﬁned
ed in units of millilitres per 100 grams per
~50 mL/100 g/min
cupied by blood 4–6 mL/100 g
by 100 g of brain in 1 min. ~3.5 mL/100 g/min
al changes in response to stimuli usually
in signal per change in CO2/O2
on dioxide in arterial blood i.e. gas PaO2: 11–13 kPa PaCO2: 4.7–6 kPa
concentration of oxygen or carbon
reath.
EtO2: 16–17% EtCO2: 5% (4.6–5.6 kPa)
gen or carbon dioxide in the air that is
ir has an FiO2 of 0.21
FiO2: 0.21 (21%) FiCO2: 0.0004 (0.04%)
olecules which are oxygenated in arterial 95–100%
d and therefore available for tissues. 20 mL O2/dL
lood created by arterioles and capillaries.
lar resistance to maintain blood ﬂow in
ood pressure to match metabolic needs.
ution of blood ﬂow from regions of
ity (maximally dilated vessels) to areas
city.
Fig. 1. Transport of gases to the tissues and their effect on cerebral blood ﬂow. (A) Oxygen
(O2) is inspired into the alveoli and passes into the arterial blood for delivery to tissues.
Carbon dioxide (CO2) produced by metabolizing cells is carried in the venous system
and expelled through the lungs in expired gas. PVO2 and PVCO2 is the partial pressure of
oxygen or carbon dioxide in venous blood. For other abbreviations see Table 1.
(B) Cerebral blood ﬂow (CBF) in the normal physiological range of O2 is stable, but CBF
increases in response to hypoxia and decreases in the presence of hyperoxia. Elevation
of CO2 causes a linear increase in CBF except at the extremes, where vasoactive
properties are exhausted, producing a sigmoid curve.
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nique. Vasoreactivity may be measured by applying a “challenge” such
asmodiﬁcation of arterial gas concentration or the vasodilator acetazol-
amide (Vagal et al., 2009b). Acetazolamide is thought to work by caus-
ing inhibition of erythrocyte carbonic anhydrase resulting in impaired
clearance of CO2 and acidosis which causes vascular smooth muscle re-
laxation. This causes an increase in CBF, without affecting CMRO2
(Vorstrup et al., 1984). Usually administered with a standard dose of
1000 mg, it is safe and usually well tolerated, without changes in sys-
temic parameters (Vagal et al., 2009a). There are a number of disadvan-
tages including side effects such as paraesthesia and headaches, along
with reports of reversible neurological deﬁcts thought to be secondary
to ischaemia (Komiyama et al., 1997). It has a number of drug interac-
tions and must also be used with caution in subjects with hepatic or
renal dysfunction or electrolyte disturbances, limiting its use in some
patient groups (Eskey and Sanelli, 2005). Its lack of reversibility means
it can only be used once in anMRI sessionwhereasmodiﬁcation of arte-
rial gas concentration, or “respiratory challenge” is reversible and more
versatile.
The use of a challenge uses the individual as their own control and
negates some of the problems of direct measurement (Eskey and
Sanelli, 2005). CBF, and hence CVR, can be measured by MRI sequences
including arterial spin labelling (ASL) or dynamic susceptibility contrast
perfusion MRI (Wintermark et al., 2005).
Changes in vessel calibre in response to a challenge can lead to
changes in other parameters such as oxygenation and cerebral blood
volume, measurable by other MRI techniques (see below). Therefore
the percentage change seen in respiratory challenge MRI is deﬁned as:
%change ¼ MRI parameterpostchallenge−MRI parameterbaseline
MRI parameterbaseline
 100:
For standardization of signal change, it should be corrected for the
change in gas concentration delivered to, or expired by, the subject.
Therefore the general formula for deﬁning CVR in respiratory challenge
MRI is:
CVR ¼ MRIparameterpostchallenge−MRIparameterbaseline
MRIparameterbaseline
 100
Gas½ postchallenge− Gas½ baseline
:
2.1. Gases
O2 and CO2 havewell described effects on cerebral vessel calibre and
blood ﬂow (Kety and Schmidt, 1948a). Effects are rapid and reversible,
with minimal side effects. Rapid initiation and cessation of a gas chal-
lenge allows repeated measurements during MRI (unlike acetazol-
amide, whose effects are long-lasting). Thus the ability to interrogate
vasoreactivity by measuring vascular response to changes in O2 and
CO2 may be useful to investigate cerebral pathophysiology.
2.1.1. The physiology of gas transport
Air, comprising 21% O2 and 0.04% CO2, is breathed in through the
mouth andnose, and conducted to the lungs by the trachea and bronchi,
which form anatomic dead space (i.e. they do not take part in gas ex-
change). Inspired air mixes with gas in the conducting airways. Within
the alveoli, O2 diffuses into capillaries and is transported to the heart.
Most O2 (N98%) is carried bound to haemoglobin within red blood
cells, as oxyhaemoglobin, but the remaining amount is transported in
arterial blood as a dissolved gas (referred to as the PaO2). The CaO2 is
the total oxygen content of the arterial blood, including both dissolvedand bound O2. It is calculated by the O2 content equation (Chambers
et al., 2015):
CaO2 ¼ 1:34Hb SaO2100
 
þ 0:023 PaO2ð Þ
Where:
CaO2 = arterial oxygen content (mL/dL)
Hb = Haemoglobin (g/dL)
SaO2 = arterial oxygen saturation (%)
PaO2 = arterial partial pressure of oxygen (kPa).
Once arterial blood arrives in tissues, the acidic and hypercarbic en-
vironment along with reduced PaO2 causes O2 to be released from
haemoglobin.Metabolizing tissues release CO2which diffuses from cap-
illaries into the venous circulation. CO2 is transported as either as a dis-
solved gas, bicarbonate (HCO3–), or bound to proteins. In the lungs, CO2
diffuses into the alveoli, and is expired via the airways (Fig. 1A). End-
tidal CO2 is the partial pressure of CO2 at the end of an exhaled breath.
Normal EtCO2 is 4.0–5.7 kPa, and is 0.3–0.7 kPa lower than PaCO2 due
to the mixture of gas in alveolar dead space. In normal healthy individ-
uals, the difference is negligible but this becomes more marked in car-
diac and pulmonary disease, as well as with increased age and
smoking, due to increased dead space. This is also the case for differ-
ences in EtO2 and PaO2 (Bengtsson et al., 2001).
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CO2 is one of the most important modulators of vascular tone, with
increased CO2 (hypercapnia) leading to a relaxation of vascular smooth
muscle and increased CBF. For each 1 mm Hg increase in PaCO2, CBF
increases by 1–2 mL/100 g/min (Brian, 1998; Kety and Schmidt,
1948a). This relationship is characterized by an sigmoidal curve, with
attenuated responses at the extremes (Reivich, 1964) (See Fig. 1B). Re-
sistance arterioles (40–100 μm) are more responsive to hypercapnia
than larger arterioles (up to 400 μm), but responses to hypocapnia are
independent of vessel size. Recent evidence has suggested that even
major vessels, such as themiddle cerebral artery, demonstrate diameter
change in response to altered carbon dioxide (Coverdale et al., 2014).
Cerebral blood volume (CBV) has a sigmoidal relationship to changes
in PaCO2 (Grubb et al., 1974).
CO2 is proposed to exert its effects after dissociating into the
vasoactive agents H+ and HCO3. Increased H+ concentrations lead
to activation of potassium channels and endothelial hyperpolarization
(Ainslie and Dufﬁn, 2009) which is relayed to vascular smooth
muscle cells. Intracellular calcium concentration reduces and vasorelax-
ation occurs (Edvinsson and Krause, 2002). Alterations in CO2 have classi-
cally been thought not to lead to a change in metabolic O2 consumption
(Kety and Schmidt, 1948a) but more recent evidence suggests hypercap-
nia may lead to altered neuronal activity (Hall et al., 2011).
Rapid CO2 diffusion across alveoli allows CBF change within 6 s
of a rise in CO2 with a CBF plateau being obtained within 45 s
(Poulin et al., 1996). However, the fall in CBF following restoration of
normocapnia is much quicker (Poulin et al., 1996). Adaptation to
sustained hypercapnia does occur, with gradual restoration of normal
CBF despite sustained hypercapnia. This occurs within hours, although
others have argued this can occur within 10 min (Ellingsen et al.,
1987). This needs to be considered when designing respiratory chal-
lenge experiments.
Side effects such as nausea, ﬂushing, hyperventilation, and transient
neurological symptoms (Spano et al., 2013) may occur with hypercap-
nia along with anxiety, sensory stimulation and a panic like disorder
(Colasanti et al., 2012). Hyperventilation induced by hypercapnia may
increase motion artefacts (Taylor et al., 2001). Ainslie and Dufﬁn
(Ainslie and Dufﬁn, 2009) recommended limiting delivery of FiCO2 to
8% for both subject safety and comfort. Despite side effects most sub-
jects tolerate hypercapnia experiments. A review of 434 CVRMRI exam-
inations using a rebreathing circuit and targeted EtCO2 of 50 mm Hg
(6.7 kPa), reported transient symptoms in 11.1% of studies, no major
complications, and successful CVR map generation in 83.9% of studies
(Spano et al., 2013). Examined patients had a variety of diagnoses in-
cluding atherosclerosis, Moyamoya vasculopathy, arteriovenous mal-
formation, vasculitis and dissection.
Hypercapnia can increase systemic blood pressure (BP) (Kety
and Schmidt, 1948a), due to activation of the sympathetic nervous sys-
tem, which may affect CVR measurements (Ainslie and Dufﬁn, 2009;
Hetzel et al., 1999). The vascular response to hypercapnia is lost when
vessels are maximally dilated in response to low systemic BP (e.g.
hypovolaemia), in an effort to maintain CBF (Grubb et al., 1974). There
is therefore a limit on the capacity to autoregulate. CVR to breath-hold
and 6% CO2 breathing showed improved correlation when changes in
blood ﬂow velocity (measured by transcranial Doppler ultrasound)
were corrected for changes in blood pressure, and thereforemonitoring
BP with compatible equipment duringMRI experiments should be con-
sidered (Prakash et al., 2014).
2.1.3. Oxygen
Within normal physiological values, changes in PaO2 have little ef-
fect on vessel radius or CBF (see Fig. 1) (Watson et al., 2000). Once
PaO2 drops below 6.7 kPa, metabolic signals such as adenosine, along
with the direct action of hypoxia on vascular smooth muscle, results
in vasodilatation and increased CBF, allowingO2 delivery to remain con-
stant (Golanov and Reis, 1997). MRI experiments using hypoxia havebeen performed, usually in young healthy individuals (Noth et al.,
2008). Hypoxic experiments require well controlled experimental con-
ditions and may be inappropriate in patients.
The effects of hyperoxia are less clear but most studies have sug-
gested it causes a reduction in CBF. In young healthy subjects blood
ﬂow, measured using phase-contrast MR angiography, decreased by
up to 25% when a 100% oxygen was administered (Watson et al.,
2000). Bulte and colleagues, using arterial spin labelling (ASL)MRI, pro-
posed that CBF decreased even with minor hyperoxia, and continued to
decline as FiO2 increased (Bulte et al., 2006). Hyperoxia is proposed to
have a direct vasoconstrictive effect on vessels via the attenuation of
the effects of nitric oxide (Demchenko et al., 2000). This ismoremarked
with hyperbaric O2 (Omae et al., 1998). However the effect of hyperoxia
is complicated by two factors. Firstly hyperoxia leads to a small but sig-
niﬁcant reduction in EtCO2 probably due to increased tidal volume. Re-
duced EtCO2 leads to vasoconstriction, and this may be responsible for
the change in CBF seen with hyperoxia. When changes in EtCO2 were
corrected for in a phase-contrast MRI experiment, changes in FiO2 did
not have a signiﬁcant effect on CBF, suggesting CO2 is the predominant
modulator of CBF (Xu et al., 2012). The second factor is that oxygen
changes the MR relaxation properties of tissue and blood, which may
have profound effects on measurements, particularly when using ASL.
Adjustment for this may be required for the accurate quantiﬁcation of
CBF (Pilkinton et al., 2012).
Studies using hyperoxia may therefore need to consider the mea-
surement and control of CO2 and correct for changes in T1, which
adds to the complexity of the experimental paradigm.
Hyperoxia can be used alone, or in combination with CO2 (carbogen)
in respiratory challenge experiments. Carbogen increases both CBF and
PaO2.
As well as affecting CBF, O2 has important effects on the BOLD signal
in fMRI. With a FiO2 of 21% and normal atmospheric pressure, arterial
haemoglobin (Hb) is almost completely saturatedwith O2 (creating dia-
magnetic oxyhaemoglobin). Elevated FiO2 increases the amount of gas
dissolved in plasma in linear proportion to the partial pressure
(Kalamangalam et al., 2012). This dissolved paramagnetic O2 alters the
susceptibility between blood and tissue. It also has an effect via the
oxygen-haemoglobin dissociation curve. Due to the increased PaO2
in the capillaries, there is a reduction in the dissociation of O2 from
haemoglobin as the PaO2 does not fall sufﬁciently to allow its release.
In conditions of hyperoxia therefore, the amount of deoxyhaemoglobin
is nearly constant during capillary transit. This results in an in-
creased T2* signal and hyperoxic BOLD contrast (Schwarzbauer and
Deichmann, 2012).
Hyperoxia is associatedwith the release of oxygen free radicals, which
may overwhelm endogenous antioxidant mechanisms, and lead to lipid
peroxidation and plasma membrane breakdown particularly in the
lungs (Jamieson et al., 1986). Reversible alveolar changes in human sub-
jects after 17 h of over 95% oxygen suggested changes in alveolar-
capillary barriers (Davis et al., 1983). Subjects may develop substernal
pain, tracheobronchial irritation, tissue destruction and pulmonary oe-
dema when FiO2 N 50% is given for prolonged periods (Jackson, 1985;
Martin and Grocott, 2013). Hyperoxia may also lead to nitrogen washout
and airway collapse (Duggan and Kavanagh, 2005). These effects occur
only after several hours to days of prolonged hyperoxia, although they
are enhanced by elevated atmospheric pressure (Jackson, 1985). The du-
ration of hyperoxia givenwithin the context of anMR experiment are not
thought to have any detrimental effects, but the “safety thresholds” for
oxygen administration remain unclear.
3. Technique
3.1. preparation
Subjects with brain diseasemay have difﬁculties with informed con-
sent and comprehension of protocols. Well planned exclusion criteria
Table 2
Standardization of confounding factors in vascular testing (adapted from (Van Bortel et al.
(2002)).
Confounding factors In practice
Room temperature Document. Be aware of increase in temperature
with prolonged scanning and plan experiments
with this in mind.
Time of day Similar time of day for repeated measurements.
Smoking Avoid for 3 h prior
Food Avoid for 3 h prior
Caffeine Avoid for 3 h prior (and exclude those with very
high intake).
Alcohol Avoid for 10 h prior
Menstrual cycle Stage in cycle recorded Aim for similar stage in
repeat measurements
Height, weight Record
Visual stimulation Speaking Ask patients not to speak and to keep their eyes
shut during reactivity testing
Haematocrit Record
Medication Record Consider withholding/excluding vasoactive
medication
Sleeping Patient should not be allowed to sleep during the
scan
Cardiac rhythm Consider if this may inﬂuence data
671F.C. Moreton et al. / NeuroImage: Clinical 11 (2016) 667–677accompanied by thorough and early screening for any contraindications
to MRI, may prevent subject drop out, avoid scanning delays and en-
hance data quality.
3.1.1. Exclusions
Normal MRI exclusion criteria should be followed (Kanal et al.,
2013). Subjects with claustrophobia or anxiety may struggle with MR
scanning, and use of a face mask within the conﬁnes of the scanner
boremay exacerbate this. Panic disorder patientsmay be hypersensitive
to the anxiety inducing effects of CO2 (Colasanti et al., 2012). Patients
with signiﬁcant pulmonary or cardiac disease may need to be excluded
from studies due to difﬁculties tolerating abnormal gas concentrations,
issues with monitoring (see Monitoring below) and accurate measure-
ment of end-tidal gases, and altered cerebral haemodynamics, such as in
atrial ﬁbrillation (Lavy et al., 1980; Petersen et al., 1989).
3.1.1.1. Oxygen. Patients requiring continuous O2 such as those with
pneumonia (relevant in acute research such as stroke) may not tolerate
periods of normoxia. Due to the potential risk of pulmonary atelectasis
from hyperoxia, patients with bronchiectasis should be excluded. Sub-
jects with type II respiratory failure have inadequate ventilation, caus-
ing a rise in resting PaCO2; hence the respiratory centre becomes
driven by hypoxaemia. Hyperoxia can reduce ventilation leading to
rises in PaCO2. Therefore patients with certain types of chronic obstruc-
tive pulmonary disease or respiratory muscle weakness (e.g. uncon-
trolled myasthenia gravis) should be excluded.
3.1.1.2. Carbon dioxide. Subjects with known type II respiratory failure
should not be subjected to hypercapnia in order to avoid further in-
crease in PaCO2. Hyperventilation (to induce hypocapnia) should be
avoided in those with a history of epilepsy as it may induce seizures
(Guaranha et al., 2005). In subjects with unruptured intracranial aneu-
rysms, conditions that cause alterations in the aneurysms transmural
pressure gradient, such as hypertension or sudden alterations in intra-
cranial pressure (ICP) secondary to hyperventilation, are proposed to
increase the risk of rupture during aneurysm surgery (Chowdhury
et al., 2014). Therefore these subjects should be excluded.
3.2. Standardization of testing conditions
Factors that may inﬂuence blood ﬂow and reactivity include time of
day (Strohm et al., 2014), nicotine (Shinohara et al., 2006), food
(Tsai et al., 2004), alcohol (Gundersen et al., 2013), body mass (Selim
et al., 2008), haematocrit (Hudak et al., 1986) and hormonal cycles
(Bartelink et al., 1990). Visual stimulation and speakingwill result in in-
creased CBF to active brain regions (Ito et al., 2001), but sleep can reduce
the cerebrovascular response to CO2 (Ainslie and Dufﬁn, 2009),
so most tests may be best performed on an awake, silent patient
with closed eyes. Numerous medications may inﬂuence cerebral
haemodynamics including cholesterol-lowering drugs (Murakami
et al., 2008), angiotensin-receptor enzyme inhibitors (Walters et al.,
2004), calcium channel blockers (Kuridze et al., 2000) and hormone re-
placement therapy (Ohkura et al., 1995), and patients may need to be
excluded or medication withheld.
Caffeine reduces cerebral blood ﬂow (Lunt et al., 2004) and thus ab-
stinence for a short period prior to a study may be advisable. However
chronic caffeine use may lead to upregulation of vascular adenosine
receptors to preserve CBF, and abstinence prior to a study could lead
to a “withdrawal” rebound increase in CBF (Addicott et al., 2009). As
this is only likely to occur in patients with very high caffeine use
(N600 mg/day or 4–7 cups of coffee) it has been suggested that these
subjects should be excluded from perfusion studies (Addicott et al.,
2009) but the exact dosage of caffeine intake can be difﬁcult to ascertain
due to the variety of sources.
Temperature is known to inﬂuence cerebral blood ﬂow (Kuluz et al.,
1993). The temperature within the bore of a magnet may increase asscanning progresses due to radiofrequency energy (Westbrook et al.,
2011). For studies using repeat imaging or prolonged scanning sessions,
an increase in temperature could therefore potentially inﬂuence perfu-
sion characteristics of the subject in the bore as theremay be an increase
in CMRO2 (Edvinsson and Krause, 2002).
Standardised conditions developed for peripheral vascular function
assessment are similarly applicable to cerebral perfusion studies, al-
though may be difﬁcult to implement in acute studies (Laurent et al.,
2006; Van Bortel et al., 2002). Table 2 reproduces some of these stan-
dards and includes others relevant to respiratory challenge MRI
experiments.
3.3. A trial run
A trial run of the challenge outside theMRIwith closemonitoring in-
cluding heart rate, blood pressure, respiratory rate and inspired and ex-
pired respiratory gas concentrations allows priming of the subject to the
experience of the respiratory challenge in a less claustrophobic environ-
ment. Subjects have the opportunity to ask questions and report side ef-
fects. Safety concernsmay also be identiﬁed prior to theMR experiment.
Compliance and experimental success is likely to be increased (Taylor
et al., 2001). Local ethics committees may require trained medical per-
sonnel to be present but this is likely to vary according to protocol and
patient group.
3.4. The respiratory challenge
The respiratory challenge should be easy to perform, tolerable, and
give reliable gas concentrations. Unfortunately these ideal requirements
are not always compatible, as highly accuratemodiﬁcations in PaO2 and
PaCO2 require a completely closed circuit and invasivemonitoring i.e. an
intubated and ventilated patient.
3.4.1. Ventilatory techniques
Ventilatory techniques, in their simplest form, do not require addi-
tional equipment, but do require patient compliance, limiting their use
in cognitive impairment, sedation or confusion. Breath-holding causes
hypercapnia and increased CBF, comparable to that achieved with 5%
CO2 (Kastrup et al., 1999; Ratnatunga and Adiseshiah, 1990). Breath
hold may occur at the end of inspiration or expiration. End-expiration
breath hold leads to an immediate rise in EtCO2, but the tolerable dura-
tion is shorter (due to hypoxia) and it may be more unpleasant for the
patient thus increasing motion artefacts (Ratnatunga and Adiseshiah,
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expiration breath hold, with lower values and a confounding inspiration
before the exhalation is measured. In comparison, end-inspiration
breath hold is longer andmore comfortable but changes in intrathoracic
pressure result in a biphasic change in BOLD signal which needs to be
factored into MRI measurements (Thomason et al., 2007; Thomason
and Glover, 2008). Both techniques are simple and practical for use in
MRI. There are concerns about experimental repeatability due to varia-
tions in breath-hold duration (Thomason et al., 2007), although as long
as EtCO2 ismeasured repeatablemeasurements can be obtained (Bright
and Murphy, 2013). Additions to the technique include visual cueing,
measurement of compliance with an abdominal pneumatic belt
and paced breathing (Scouten and Schwarzbauer, 2008; Thomason
et al., 2005), all of which add complexity and may reduce subject
acceptability.
Respiratory tasks, including breath hold, and other conditions that
result in a rise in hypercapnia, can cause confounding motion artefacts
Voluntary hyperventilation causes hypocapnia and reduced CBF
(Raichle and Plum, 1972). A period of N60 s can induce a fall of around
25% (Rostrup et al., 2005). Subjects are asked to modify their breathing
rate and depth via visual cues, for a certain period or to a target EtCO2,
which require training outsideMRI (Vogt et al., 2011). Hyperventilation
may increase motion artefacts (Naganawa et al., 2002).
3.4.2. Fixed inspiratory challenge
Delivery of a ﬁxed gas concentration via a non-rebreathing mask is
passive and easy to perform. It requires a constant gas supply and a de-
livery method. Premixed gas cylinders can be used, or gas blenders mayFig. 2. Steady-state and dynamic respiratory challenges. (A) Arterial spin labelling (ASL)MRI pe
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADA
mixture caused a change in end-tidal CO2 (B) and separate scans were performed during each
can allow the application of repeated challenges and assess temporal resolution of signal in
normal volunteers given a dual hyperoxic challenge. Changes in end-tidal oxygen concentra
signal changes. The red box represents the duration of the scan.allow more variation in gas concentrations. 5% CO2 is proposed to raise
CBF by 50% (Kety and Schmidt, 1948a) and 100%O2 to reduce CBF bybe-
tween 10% and 25% (Bulte et al., 2006) (Watson et al., 2000). Fixed in-
spiratory challenge is effective for steady-state measures, such as ASL
(62), or those with a block design, where a stimulus is given for set pe-
riods on several occasions in order to allow summation of results, usu-
ally with a continuous imaging method (Kalamangalam et al., 2012)
(Fig. 2).
A ﬁxed FiO2 or FiCO2 does not necessarily equate to a speciﬁc arterial
concentration as this depends on ventilation, metabolic rate, age, lung
function and the adequacy of the delivery circuit (Fierstra et al., 2013).
Flow rates may depend on circuit design, including the use of reservoir
bags. Circuits must be capable of supplying high enough ﬂow rate to
support the increased tidal volume seen with hypercapnia. An under-
shoot in EtCO2, may be seen following hypercapnia experiments as pa-
tients hyperventilate to expel excess CO2 (Wise et al., 2007).
Arterial concentrationsmay change evenwhen the inspired concen-
tration is kept constant e.g. increased ventilation in response to hyper-
capnia may lead to an elevated EtO2, which may inﬂuence MRI signal
(Wise et al., 2007).
For these reasons, end-tidal gas concentrations should therefore be
monitored to allow accurate signal quantiﬁcation.
3.4.3. Rebreathing
Rebreathing of exhaled gaswill result in equilibration of alveolar and
arterial gases and a gradual increase in PaCO2. It is performed with a
simple breathing circuit, with or without additional gases, and is gener-
ally well tolerated (Saunders, 1980). However the speed and values ofrformedwhilst receiving air (left) and 6% CO2/airmixture (right) in a patient with cerebral
SIL), demonstrating increased CBF in response to hypercapnia. Delivery of a 6% CO2 gas
steady state. The red box represents the duration of the ASL scans. Continuous imaging
relation to gas concentrations. In (C) T2* signal changes vary over an 11min fMRI in 4
tion for one patient receiving this challenge is shown in (D) and can be correlated with
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rebreathing circuits with ﬁxed inspiratory challenges are proposed to
achieve more stable EtCO2, but require signiﬁcant patient cooperation
(Vesely et al., 2001). Rebreathing techniques allow the measurement
of dynamic changes to a range of EtCO2 (Ainslie and Dufﬁn, 2009).
Rebreathing in a closed circuit will lead to a fall in delivered FiO2.
Isooxia should be maintained for CVR measurement and to prevent
the patient receiving a hypoxic gas mixture. Rebreathing methods
where isooxia is achieved and ETCO2 is representative of PaCO2 have
been described (for a recent review see Fierstra et al. (2013))).
3.4.4. Dynamic end-tidal forcing
More precise control of EtCO2 and EtO2 has been advocated to per-
mit more accurate adjustment of changes in MRI signal responses. Dy-
namic end-tidal forcing uses breath-by-breath computer control of
inspired gas to achieve target EtCO2 and EtO2. This may increase repeat-
ability both between subjects and sessions, and allows more complex
variations of respiratory challenges to be performed (Wise et al.,
2007). It is more expensive and complex to run than ﬁxed inspiratory
challenges, and breath-by-breath analysis can be hampered by the
need for long gas sampling lines in MRI. It requires a high ﬂow rate
and there is the potential for the delivery of an anoxic mixture although
this is avoided with use of the correct circuit (Wise et al., 2007). Issues
with the accuracy of using EtCO2 to predict PaCO2 remain (Fierstra
et al., 2013).
3.4.5. Prospective end-tidal targeting
Prospective end-tidal targeting has been a developed as amethod to
permit more accurate correlation of changes in EtCO2 with MRI signal
responses (Ito et al., 2008). A tight-ﬁtting mask is attached to a 3-
valve circuit with inspiratory and expiratory reservoirs. Gas ﬂow to
themaskmoves through a computer-controlled gas blender (Respiract;
Thornhill Research, Toronto, Canada) which supplies O2, CO2 and nitro-
gen to achieve target EtCO2 and EtO2 independent of breathing pattern.
Its advantages are that it allows rapid changes in gas concentration and
that the end-tidal gases are equivalent to that of alveolar ventilation,
and thus more accurately reﬂect tissue concentrations (Fierstra et al.,
2013). A more detailed explanation of the method is available in
Fierstra et al. (2013). It has been used to study cerebral physiology in
a number of different disease states (Fierstra et al., 2011; Heyn et al.,
2010; Mikulis et al., 2005). This method in theory could allow the inclu-
sion of patients with pulmonary disease as the EtCO2 will continue to
accurately reﬂect PaCO2 (Ito et al., 2008), although the danger of expo-
sure to hypercarbia or hyperoxia in these patients remains.
3.4.6. Motion artefacts
Respiratory challenges that result in hypercapnia or require the pa-
tient to make extreme ventilatory effort, such as breath hold, can result
in motion artefacts which may result in a measured signal difference.
This may confound the interpretation of results, particularly when a
“baseline” versus “challenge” imaging design is used. It is important to
ensure the patient is securely strapped into the head coil. Motion cor-
rection software or exclusion of patients with excessive head motion
may also be needed(Bulte et al., 2009).
3.5. The environment and equipment
Use of respiratory challenge adds complexities to the already difﬁ-
cultMR environment. As subject safety is paramount, all staff should un-
dergoMRI safety induction training as per local guidelines (Farling et al.,
2002).
3.5.1. Monitoring
Monitoring of gas concentrations is important for calculation of CVR,
but may also be required for subject safety. Access to subjects is limited
as the head is usually placed in a tight-ﬁtting receiver coil (to enhancesignal), padded and secured to limit movement. This complicates the
delivery of gas,monitoring of subjects and verbal communication. Addi-
tional equipment must be MR safe or MR conditional and effective, and
close liaison with anesthetists is recommended. Standard MR monitor-
ing equipment must be correctly positioned to avoid the formation of
inductive loops which may cause burns (Dempsey and Condon, 2001).
ECG leads are prone to interference (Farling et al., 2002) and ﬁbre
optic MR connections preferred. Anaesthetic guidelines recommend
that remote MR monitoring in the control room is available to reduce
occupational exposure to magnetic ﬁelds and hearing damage (Farling
et al., 2002; Farling et al., 2010).
Whilst respiratory challenge MRI aims to modify cerebral tissue O2
and CO2, this is difﬁcult to measure directly, and whilst arterial concen-
trations are representative they also require invasive monitoring. Non-
invasive measurement of end-tidal gases is a more straightforward, if
indirect measurement. Sampling should be performed as close to the
subject's expired air ﬂow as possible. The long sample lines necessitated
by MRI will increase the time delay between sampling and recording
(up to 20 s) (Farling et al., 2002). Secretions may block lines, and
water traps dry out the sampled air, giving a dry value for expired gas.
In normal atmospheric pressure a wet gas correction value of 0.94 can
be applied to dry gas measurements (Bengtsson et al., 2001).
Capnography involves both the measurement and display of the EtCO2
value and waveform. It offers the advantage of assessment of circuit in-
tegrity (i.e. a reasonable seal) and allows identiﬁcation of leaks or un-
planned buildup of CO2.
There does however remain some question as to the accuracy of
end-tidal measurements. Use of EtCO2 may only be appropriate with
use of regression equations to adjust for changes in tidal volume, as ven-
tilationwill increase with a rise in delivered carbon dioxide (Ainslie and
Dufﬁn, 2009). Use of prospective end-tidal targeting may offer advan-
tages over unadjusted end-tidal gas readings (Ito et al., 2008;
Slessarev et al., 2007).
3.5.2. Gas delivery
3.5.2.1. Nasal cannula. Nasal cannulas are simple, cheap and well toler-
ated, allowing unimpeded verbal communication. Tolerability is re-
duced with high ﬂow rates as this can cause painful drying of the
nasal mucosa. The main disadvantage is that patients can still mouth
breath, although explanation may reduce this. It is possible to deliver
1–6 L/min of O2 (24–44%) and ﬁxed concentrations of CO2 (Cantin
et al., 2011). There is greatly reduced control over inspired fractions,
even with exclusive nasal breathing, as each patient entrails a different
fraction of room air depending on their tidal volume. Normal nasal can-
nulas do not allow the monitoring of end-tidal gases but nasal cannulas
with O2/CO2 combinationmonitoring are available. An alternative is the
use of a mouth piece with nasal clip (Yezhuvath et al., 2012). However
communication is hampered and patients may still be able to entrain
room air from around the mouth piece.
3.5.2.2. Face mask. Standard vented face masks are available which can
deliver FiO2 up to 60% using 5-10L/min (Marino, 2013). Normal air
can be breathed in through the vents, diluting the delivered gas concen-
trations. Most subjects will ﬁt thesemasks and the seal can be improved
by the use of tape. They are generally well tolerated but when used in a
narrow head coil, theymay be uncomfortable and result in subject drop
out (Cantin et al., 2011).
3.5.2.3. Non-vented face mask. A non-rebreather mask or anaesthetic
mask (non-vented), offers amuch improved seal and reducedmask vol-
ume resulting in more controlled gas delivery and sampling. However
the tight ﬁtmaymake them less tolerable to patients and their structure
is less malleable than standard face masks making them more difﬁcult
to ﬁt into MRI head coils. Modiﬁed masks have been used to allow ﬁt
(Shen et al., 2011). As these masks are non-vented they create the risk
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an appropriate breathing circuit such as a uni-directional valved circuit
with a gas reservoir for safety (Shen et al., 2011; Tancredi et al., 2014).
Thesemay improve the reliability of CBF experiments (Cain et al., 2013).
4. MRI sequences and examples of use in brain disease
4.1. BOLD signal: fMRI and SWI
Functional MRI using gradient-echo echo-planar imaging with
strong T2* weightingmeasures the blood-oxygenation level dependent
(BOLD) signal. Oxyhaemoglobin is diamagnetic and has limited effect
on T2*-weighted signal. Deoxyhaemoglobin is paramagnetic and leads
to a reduction in T2*-weighted signal. The BOLD signal depends on
CBF, CBV, cerebral metabolic rate of oxygen (CMRO2), haematocrit and
PaO2,although in healthy subjects it is dominated by CBF (Shiino et al.,
2003).
Hypercapnia-induced CBF increase “washes out” deoxyhaemoglobin
causing an increase in T2* weighted signal (Shiino et al., 2003). The sig-
nal difference between normocapnia and hypercapnia can be used to
measure CVR. Validation studies using 15O PET have been used
to compare BOLD signal change to relative CBF change in healthy volun-
teers(Rostrup et al., 2000) In 25 patients with arterial steno-occlusive
disease there was a strong correlation between hemispheric CVR
using BOLD MRI and ASL MRI (Mandell et al., 2008). In Moyamoya dis-
ease, CVR correlatedwith severity and the presence of collaterals (Heyn
et al., 2010). CVRmapping performed pre and post-operatively showed
areas of vascular steal correlating with severe stenosis, which was re-
solved following successful revascularization, suggesting CVR mapping
could be used for pre-operative planning (Mikulis et al., 2005) (Han
et al., 2011). CO2 challenge also demonstrated impaired CVR around ar-
teriovenous malformations in those patients prone to seizures com-
pared to those without a history of seizure (Fierstra et al., 2011).
In hyperoxic states, the extra dissolved O2 means oxygen remains
bound to haemoglobin and results in a reduced concentration of
deoxyhaemoglobin in tissues thereby increasing T2* signal.We have in-
vestigated O2 challenge T2*-weighted MRI in subjects with stroke
within 24h of onset. The putative infarct core showed diminished T2*-
weighted signal increase compared to normal tissue, suggesting this
technique may be able to tease out changes in metabolic activity (Dani
et al., 2010). The technique has recently been validated in rodent
models using T2* oxygen challenge with measurements of CBF
(Robertson et al., 2015). O2 challenge T2*-weighted MRI has also been
investigated in temporal lobe epilepsy, with 7/10 patients showing
changes in T2* responses identifying seizure lateralization including
two patients with normal MRI scans (Kalamangalam et al., 2012).
BOLD imaging allows the use of continuous measurements and as-
sessment of dynamic responses to altered gas concentrations. In pa-
tients with Alzheimer's disease, maximal BOLD signal took longer to
achieve than in normal controls suggesting some vasomotor impair-
ment (Cantin et al., 2011).
BOLD imaging with a respiratory challenge has therefore been used
to: demonstrate physiological impairments such as reduced vascular re-
serve and vascular steal phenomenon; conﬁrm disease laterality; corre-
late with clinical outcome measures; and to plan and predict surgical
outcomes of revascularization.
Susceptibility-weighted imaging (SWI) is an alternative sequence
sensitive to BOLD signal, and shows cerebral venous architecture and
iron-containing tissues with high-spatial resolution. Expected BOLD re-
sponses to carbogen (95% O2, 5% CO2) and hyperoxia challenges have
been detected in normal volunteers using SWI (Rauscher et al., 2005).
Heterogeneous tumour response to carbogen and O2was demonstrated
in two patients with glioma, indicating tissue heterogeneity caused
by necrotic, oedematous tissue and abnormal neovascularization
(Rauscher et al., 2005). As tumour responsiveness to radiotherapy
may be increased with increased tumour O2 levels (Gray et al., 1953),investigation of oxygenation and ﬂow within brain tumours may aid
disease management. SWI offers a way of imaging regional BOLD
changes with high spatial resolution (Rauscher et al., 2005). However
SWI is susceptible to motion artefacts which may be more likely to
occur with higher FiCO2 (Sedlacik et al., 2008).
CVR assessmentmay also be used to exclude patients with impaired
CVR from fMRI studies, due to the risk of abolished BOLD responses in
these patients (Krainik et al., 2005).
4.2. Perfusion
Arterial spin labelling (ASL) imaging involves magnetically labelling
protons in the arterial blood supply. As this blood passes into the brain,
it causes a small signal loss in brain tissue compared to non-labelled im-
ages, which allows measurement of CBF. When used with a challenge,
paired blood ﬂow measurements, i.e. a baseline and then a stimulus,
can be obtained allowing calculation of CVR. ASL offers the advantages
of being non-invasive, repeatable, and quantiﬁable, but has the
disadvantage of low signal-to-noise ratio in comparison to dynamic sus-
ceptibility weighted contrast methods for investigating perfusion
(Wintermark et al., 2005). Arterial occlusion can lead to vessel-based ar-
tefacts in collateral circulation. These problems can be improved with
high-ﬁeld MRI and/or non-continuous ASL sequences.
ASL has been validated in conditions of rest, activity andhypercapnia
challenge against 15O PET (Chen et al., 2008). Brain perfusion in demen-
tia has been investigated using ASL and a 5% CO2 challenge in 49 pa-
tients. Regional CBF (rCBF) was lower and CVR impaired in frontal and
temporal cortices of Alzheimer's disease patients, compared patients
with in vascular dementia (Gao et al., 2013). Transcranial Doppler
ultrasound (TCD) failed to demonstrate any difference in blood velocity
or CVR. If regional patterns distinguish different types of dementia,
this may offer an advantage over global measures of ﬂow such as TCD.
A rebreathing challenge was used to demonstrate an association be-
tween high cardiovascular risk proﬁle and impaired hippocampal
vasoreactivity in mild cognitive impairment (Glodzik et al., 2011),
which was more sensitive than baseline CBF or brain volume. ASL
performed with hypocapnic hyperventilation and CO2 rebreathing
(95%O2, 5% CO2) challenges in 39 chronic large territory stroke patients,
demonstrated reduced ipsilateral CBF but widespread impaired
vasodilatory capacity with preserved vasoconstriction. This demon-
strated that impaired vasoreactivity extends beyond the infarcted
region. The continuous ASL technique has been shown to be quantiﬁ-
able, although the long transit times seen in strokemay lead to underes-
timation of blood ﬂow in stroke patients (Zhao et al., 2009). This is
because the ﬂow is so slow, that the signal decays by the time it has
reached the tissue being imaged.
Perfusion imaging with gadolinium bolus tracking is less commonly
used in respiratory challenge experiments due to it being less easily re-
peated, requiring IV access, and gadolinium contrast having safety con-
cerns in the face of extravasation or impaired renal function. MRI bolus
tracking and acetazolamide challenge was used in 15 patients with
CADASIL (cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy) to show impaired perfusion and re-
activity in white matter hyperintensities (Chabriat et al., 2000) and we
are currently undertaking both ASL and gadolinium bolus tracking with
CO2 challenge in 22 CADASIL patients.
4.3. Dual echo imaging (BOLD and perfusion)
BOLD and ASL can be used in sequence to provide information about
the cerebrovascular system. Using both methods can permit the assess-
ment of multiple measures of cerebral haemodynamics including CBF,
CVR, BOLD CVR, oxygen extraction fraction and CMRO2(Bulte et al.,
2012; Gauthier et al., 2012; Wise et al., 2013). In a study of patients
with internal carotid artery occlusion, BOLD CVR signal was lower in
the affected middle cerebral artery territory (De Vis et al., 2015).
Table 3
Proposed recommendations for conducting a respiratory challenge MRI experiment.
Perform a trial run of the gas challenge with the subject outside the scanner to
assess tolerability and optimize subject compliance.
Standardize testing conditions by following published guidelines for performing
vascular tests including those outlined in Table 2.
Record delivered and end-tidal gases, along with respiratory rate and heart rate to
ensure patient safety and to allow correlation with signal change. These values
can then be used for quantiﬁcation of the change in MR parameter.
If examining steady-state effects of hypercarbia or hyperoxia, allow sufﬁcient time
for steady-state to be obtained.
Liaise with anesthetists and MR physics department to ensure breathing apparatus
and monitoring equipment is safe and MR appropriate.
Exclude patients with signiﬁcant pulmonary or cardiac disease.
Ensure the gas supply is sufﬁcient to support increases in minute ventilation.
Use a maximum FiCO2 of 8% to avoid subject discomfort unless speciﬁcally
indicated (Ainslie and Dufﬁn, 2009).
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ASL) has also been used in combination with BOLD in patients with ce-
rebrovascular disease. BOLD signal change and CBF reactivity correlated
signiﬁcantly in response to carbogen, and was able to identify disease
lateralisation in steno-occlusive carotid disease, although its application
remains complex (Faraco et al., 2015). The use of BOLDand carbogen re-
sults in an increase in BOLD signal both due to increased ﬂow and in-
creased partial pressure of oxygen, and therefore its use for calculation
of CVR is complex and can lead to misleading results (Hare et al., 2013).
4.4. Cerebral blood volume: VASO
Cerebral blood volume (CBV) has a linear relationship to changes in
PaCO2 but a non-linear relationship to changes in CBF (Grubb et al.,
1974). The vascular space occupancy (VASO) technique is a CBV-
weighted imaging technique which measures change in extravascular
parenchymal signal. It has better spatial resolution than BOLD, but
poor signal-to-noise ratio. It has been used to demonstrate signal de-
creases (suggesting increased intravascular blood volume) in grey mat-
ter in response to short periods of breath-hold in normal volunteers and
patients with a meningioma (Hsu et al., 2012). More negative VASO re-
activity in response to breath-hold challenge was seen in patients with
ICA stenosis compared to controls, proposed to represent haemody-
namic impairment(Donahue et al., 2009). Using VASO with BOLD tech-
niques may help extract the inﬂuence of CBV on the BOLD signal in
disease states.
4.5. Other
Other MRI sequences have also been used with respiratory chal-
lenge. Hyperventilation is known to provoke epileptiform activity, and
was used to compare changes in diffusion (ADC) of temporal lobe epi-
lepsy (TLE) patients with controls. TLE with hippocampal sclerosis pa-
tients showed higher baseline ADC in the abnormal hippocampus and
a signiﬁcant decrease in ADC compared to controls. Altered ADC at base-
line is thought to represent altered cellular organization with the
decrease in ADC with hyperventilation (and hypocapnia) caused
by altered cellular permeability, cellular swelling and reduced extracel-
lular space (Leonhardt et al., 2002). Gadolinium-DTPA infusion with
gradient-echo imaging, accompanied by T2* weighted imaging, has
been used to study contrast uptake inmeningiomas. A hyperoxic hyper-
capnic challenge improved tumour oxygenation and increased contrast
uptake rate in 6 out of 10 patients, who the authors proposed may be
more responsive to radiotherapy with hyperoxygenation (Rijpkema
et al., 2004).
5. Recommendations
Despite the variety of techniques available, application of respiratory
challenge MRI may beneﬁt from some standardization. Subject with-
drawalmay be reduced by ensuring the recruitment of subjects without
MR or gas exclusions and undertaking a trial run of the procedure out-
side the MR scanner (Taylor et al., 2001). Whilst centres will vary in
the availability of equipment or expertise to use certain challenges or
MR sequences, recording subject parameters and standardizing testing
conditions may reduce testing variability and allow studies to be com-
pared more readily. Some proposed recommendations for the conduct
of respiratory challenge MRI studies are outlined in Table 3.
6. Conclusions
Respiratory challenge MRI has the potential to be widely used in the
assessment of brain diseases due to its safety, tolerability and repeat-
ability. Whilst problems remain with reliable gas administration, it has
been used to provide valuable insights into brain pathophysiology. Forsuch techniques to function as biomarkers to assess disease progression
or treatment response, standardization of testing is important.
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